IDEXX Laboratories stock steadies after strong Q2 2026 results and raised outlook

IDEXX Laboratories stock is trading below its recent highs, but strong Q2 2026 figures and a raised full-year outlook keep the diagnostics specialist on many investors' watchlists.

IDEXX Laboratories stock (ISIN US45168D1046) is trading below its recent peak, with a last quoted level of 529.29 USD on Nasdaq as of September 3, 2026, reflecting a daily decline of 1.80% and a year-to-date performance of minus 2.90% according to market data from Zonebourse.

Q2 2026 earnings show double-digit revenue growth

According to an overview of recent SEC disclosures compiled by StockTitan, IDEXX Laboratories reported strong second-quarter 2026 results, underlining the resilience of its veterinary and diagnostics business.

For Q2 2026, IDEXX Laboratories posted revenue of 1,217 million USD, which represents an increase of 10% on a reported basis and 9% organic compared with the same quarter a year earlier, highlighting solid expansion across key segments.

Diluted earnings per share in Q2 2026 came in at 4.27 USD, up 18% year over year, while comparable EPS reached 4.07 USD, an increase of 15% versus the prior-year quarter, indicating that profitability improved faster than sales growth.

The company also expanded its margins: the Q2 2026 gross margin reached 64.0%, and operating margin stood at 35.0%, with both metrics improving by 140 basis points compared with Q2 2025, a development that underscores operating leverage in the business model.

Guidance for fiscal 2026 raised on segment strength

On the back of these figures, IDEXX Laboratories raised its full-year 2026 outlook, now guiding for revenue in a range between 4,700 million USD and 4,745 million USD, which corresponds to reported growth of 9.1% to 10.3% and organic growth of 8.5% to 9.7% versus fiscal year 2025.

The revised guidance also includes an expected operating margin between 32.3% and 32.5% for fiscal 2026, implying that the company aims to keep most of the recent margin gains, which is relevant for investors focused on cash generation and return on capital.

For earnings, IDEXX Laboratories now anticipates full-year 2026 diluted EPS in a corridor of 14.69 USD to 14.94 USD, which management associates with 12% to 14% reported EPS growth and 13% to 15% comparable EPS growth compared with the previous year, a quantified outlook that sets clear expectations for the market.

Segment data in the Q2 2026 report show broad-based development: Companion Animal Group revenue rose 9% as reported and 8.7% organic, driven in particular by diagnostics recurring revenue, which increased 11.0% reported and 10.3% organic versus Q2 2025.

Other divisions contributed as well: Water business revenue grew 14.8% reported and 13.0% organic, while Livestock, Poultry and Dairy revenue advanced 10.8% reported and 9.0% organic year over year in Q2 2026, illustrating that IDEXX Laboratories is seeing demand across multiple diagnostics end markets.

Veterinary diagnostics as core product driver

A central pillar of IDEXX Laboratories' business is its veterinary diagnostics platforms used in small animal practices, which generate recurring revenue through consumables and services linked to installed equipment.

The Q2 2026 numbers underline this dependence: diagnostics recurring revenue within the Companion Animal Group increased by more than ten percent organic compared with Q2 2025, showing that clinics are running more tests and that utilization of installed instruments remains high.

Stock valuation and investor perspective

At a price of 529.29 USD as of September 3, 2026, IDEXX Laboratories stock trades notably below its earlier highs, while year-to-date performance of minus 2.90% and a five-day variation of minus 2.90% according to Zonebourse data indicate that the market is cautious despite the raised guidance.

IDEXX Laboratories stock at a glance

• Company: IDEXX Laboratories, Inc.
• ISIN: US45168D1046
• Ticker: IDXX
• Trading venue: NASDAQ
• Price (as of September 3, 2026): 529.29 USD
• Market capitalization: Not specified (as of latest available data)
• Sector / Industry: Health Care / Diagnostics
• Index membership: S&P 500